The association of DNMT3A mutations with poor prognosis [13]–[15] and the functional effects of DNMT3A mutations on human cells and mouse tumor models [14], [18] suggest that the loss of the enzymatic activity can drive tumorigenesis by inducing tumor-promoting epigenetic lesions. The gene discussed is DNMT3A; the disease is neoplasm.